Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as mRNA-1365 (Profile 2)
mRNA-1365 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| mRNA-1365 (Profile 2) Dose Level 1 | EXPERIMENTAL | Participants will receive 1 injection of mRNA-1365 (Profile 2) at Dose Level 1 on Day 1. |
| mRNA-1365 (Profile 2) Dose Level 2 | EXPERIMENTAL | Participants will receive 1 injection of mRNA-1365 (Profile 2) at Dose Level 2 on Day 1. |
| mRNA-1365 (Profile 2) Dose Level 3 | EXPERIMENTAL | Participants will receive 1 injection of mRNA-1365 (Profile 2) at Dose Level 3 on Day 1. |
| mRNA-1345 (Profile 1) | ACTIVE_COMPARATOR | Participants will receive 1 injection of mRNA-1345 (Profile 1) on Day 1. |
| mRNA-1345 (Profile 3) | ACTIVE_COMPARATOR | Participants will receive 1 injection of mRNA-1345 (Profile 3) on Day 1. |
| Name | Type | Description |
|---|---|---|
| mRNA-1365 (Profile 2) | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1345 (Profile 1) | BIOLOGICAL | Sterile liquid for injection |
| mRNA-1345 (Profile 3) | BIOLOGICAL | Sterile liquid for injection |
Key Inclusion Criteria: * In good general health or with stable chronic medical conditions, as determined by medical evaluation including medical history and physical examination. * Body mass index within the range 18.5 to 35 kg/m2 (inclusive). Key Exclusion Criteria: * History of anaphylaxis or ...
mRNA-1365 is an investigational messenger RNA vaccine being developed for the prevention of Respiratory Syncytial Virus (RSV) infection. It is also being studied for protection against Human Metapneumovirus (hMPV), as the ongoing clinical trial evaluates both conditions in older healthy adults.
mRNA-1365 targets the RSV prefusion F glycoprotein and the hMPV F protein. These are surface glycoproteins that enable the viruses to enter host cells, and the vaccine is designed to elicit an immune response against them.
mRNA-1365 is being developed by Moderna, Inc., a biotechnology company traded on the Nasdaq under the ticker symbol MRNA. The company is conducting a Phase 1 clinical trial to evaluate the vaccine's safety and immunogenicity.
mRNA-1365 is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The ongoing Phase 1 trial is actively recruiting participants to assess its safety, reactogenicity, and immunogenicity.
mRNA-1365 is being evaluated in a single Phase 1 clinical trial registered as NCT07764237. This randomized, double-blind, active-controlled study is recruiting 375 healthy adults aged 60 years and older in Canada and the United Kingdom to investigate the vaccine's safety and immune response.
Yes, mRNA-1365 is also referred to as mRNA-1365 (Profile 2). The clinical trial NCT07764237 explicitly uses the name mRNA-1365 (Profile 2) to describe the vaccine being studied, indicating that this is the same investigational product.